Introduction
Approximately 80% of patients with acute promyelocytic leukemia (APL) are cured with modern All-trans-retinoic acid (ATRA) and chemotherapy (1). As for patients who relapse after this regimen, arsenic trioxide (ATO) with or without other agents is considered the treatment of choice as it produces second molecular remission rates of up to 80% (2, 3) . Available options for consolidation after remission re-induction include continued ATO and/or chemotherapy plus ATRA, with or without autologous or allogeneic transplants (1). However, the best option for consolidation therapy for APL in second complete remission is still unknown. Selection of the appropriate consolidation depends on variables which include patient age and performance status, duration of first remission, donor availability, and minimal residual disease status after salvage therapy (as determined by nested RT-PCR or quantitative PCR of PML/RARA fusion gene) (1, 3).
Due to the very low number of relapses and the above variables, appropriately designed randomized studies to compare the different consolidation approaches in CR2 are deemed not feasible.
While the graft-versus-leukemia effect of allogeneic transplant offers the best anti-leukemia activity in patients with advanced disease, its success is notoriously hampered by transplant-related mortality which increases considerably in the matched unrelated and haploidentical settings (4, 5) . Therefore, allogeneic transplant in APL is generally recommended for patients failing to achieve first or second molecular remission, or in those experiencing short duration of first remission (1, 3).
To date, four major studies explored the role of allogeneic transplants in adult APL patients in the ATRA era (4, (6) (7) (8) . We previously reported a single center study on the outcome of allogeneic transplant in 17 relapsed APL patients for whom pre-transplant minimal residual disease (MRD) assessment was available. We documented a significant anti-leukemic effect of allogeneic transplant even in patients with advanced disease including those with pre-transplant evidence of MRD (6) . A survey conducted by the European Bone Marrow Transplant on a large number of cases showed that allogeneic transplant significantly reduced relapse rate compared to autologous transplants.
However, this benefit was at the expense of increased transplant-related mortality that reached 24±5% (4) . Major limitations of this large survey were the lack of information on pre-transplant treatments and status of MRD prior to transplant. None of the previous studies specifically focused on the role of allogeneic transplant after the advent of arsenic trioxide. Here we report on results of transplant in advanced APL patients treated in the ATRA and ATO era whose diseases were monitored by RT-PCR prior and after transplant.
Design and methods

Pre-transplant and transplant characteristics
Data on 31 APL patients (median age 39 years, range 16-55 years) with genetically confirmed APL who received allogeneic transplants were collected from 5
Italian transplant centers (Universities of Tor-Vergata and La Sapienza of Rome, University of Bologna, University of Perugia and San Martino Hospital, Genova). All patients with APL undergoing allogeneic transplants in these institutions between July 2000 and July 2010 were included. None of these patients was included in our previous report (6) . All protocols received approval from the corresponding IRB and/or ethical committees. Patients were treated accordingly after signing informed consent. Reversetranscriptase polymerase chain reaction the identification and monitoring of the PML/RARΑ hybrid gene was carried out at local institutions following the standardized procedures described by the Biomed-I concerted action (9) . In all cases, post-transplant relapses were confirmed by RT-PCR amplification of the PML/RARΑ hybrid gene. Main patient characteristics at first diagnosis, treatment prior to transplant, pre-transplant RT-PCR status and transplant characteristics are summarized in Table 1A Fifteen patients received transplants in CR2 and 16 in CR3 or beyond (Table 1B) .
Median time from remission to allogeneic transplant was 5 months (range 1-18 months).
At the time of transplant, 15 patients were in molecular and 16 in hematologic complete remissions with RT-PCR-positive for PML/RARA (Table 1A ). The type of transplant, conditioning regimens, GVHD prophylaxis, and status at last follow up is shown in Table   1B . Eighteen patients were transplanted from HLA identical siblings (Id-sib), 6 from matched unrelated donors (MUD) and the remaining 7 patients received haplo-identical transplant. Peripheral blood and bone marrow were the sources in 18 and 13 patients, respectively. Thirty patients received myeloablative conditioning regimens which were TBI-based in 15 and chemotherapy-based in 15 patients. One patient (UPN9) received reduced intensity conditioning regimen. Graft-versus-host-disease prophylaxis included cyclosporine A with short course of methotrexate (26 patients), together with antithymocyte globulin (2 patients) and antithymocyte globulin (ATG) alone (3 patients).
End points definition and statistical studies Median follow-up of the whole series was 55 months (range 4-100 months).
Graft-versus host-disease (GVHD) was graded as described elsewhere (10) . Unadjusted time-to-event analyses were performed using the Kaplan-Meier estimate. Overall survival was calculated from the transplant date to death or last follow up, cumulative incidence of relapse (CIR) was calculated from the date of transplant to relapse (hematologic or molecular), persistence of PCR-positivity post-transplant or to date of last follow-up for patients alive in molecular remission, using the cumulative incidence method and considering death in remission as competing risk. The log-rank test was used to compare risk factor categories for the Kaplan-Meier and the cumulative incidence curves.
Transplant-related mortality was defined as all causes of non-leukemic deaths. Kaplan
Meier curves and log-rank analysis were performed using the program R-2.11.0.
Results and discussion
Fourteen of 31 patients (45%) are presently alive in complete remission at a median follow-up of 55 months (range 4-100 months) after transplant. A total of 13 patients relapsed after transplant, of whom 11 died of disease progression at median of 8 months (range 3-59 months). The two remaining patients, one with molecular and the other with hematologic and CNS relapse achieved a new molecular remission after ATO plus ATRA and tamibarotene followed by ATO and radiotherapy, respectively. Nonleukemia death was reported in 6 cases (GVHD grade IV in 2, multiorgan failure in one, CMV pneumonia in one, unspecified infection in two patients) and 4-year cumulative incidence of transplant-related mortality was 19.6%.
A total of 15 patients developed acute GVHD: liver Grade III-IV (4 patients), skin Grade I-II (10 patients) and skin Grade III (1 patient). Chronic GVHD occurred in 7 patients, as limited skin (3 patients), extensive skin (1 patient) and intestinal GVHD (3 patients).
The probability of survival at 4 years was 45% for the whole study group, 62%
and 31% for patients transplanted at CR2 and ≥ CR3, respectively (p=0.05, Figure 1A ).
There was a significant difference in the 4-year OS between patients transplanted in molecular remission and those transplanted in hematologic remission but RT-PCRpositive at transplant time (64% and 27%, respectively (p=0.03, Figure 1B) . The 4-year CIR was 38% for all patients, 32% and 44% for patients transplanted at CR2 and ≥ CR3, respectively (p=0.37, Figure 2A) . Similarly, the 4-year CIR was lower in patients transplanted while in molecular remission compared to those in remission but with RT-PCR-positive disease at transplant (30% and 47%, respectively with p=0.30, Figure 2B ).
We acknowledge that compared to previous reports on allogeneic transplants in APL, our study includes a limited series from selected institutions. However, we provide detailed information on molecular disease status pre-transplant which is lacking in the majority of larger studies reported to date (4). This information allows much better evaluation of transplant efficacy, particularly in patients with persistent molecular disease and/or in advanced phase who had previously received state of art therapy. All but 2 patients in our series had received the AIDA protocol as front-line and more than half received ATO as a salvage therapy. Moreover, 24 of the 31 cases had very advanced disease and poor Previous studies have reported a lower relapse rate in patients receiving allogeneic transplants compared to those given autologous transplants in CR2. These results were however counterbalanced by a high transplant-related mortality rate of up to 40% (4, 7, 8, 11) . Here, we report a 4-year cumulative incidence of mortality of 19.6% in a series that Allogeneic transplant continues to be the preferred consolidation option in relapsed APL patients who are eligible for this treatment approach. Hence, search for a donor is recommended immediately after relapse is diagnosed. However, in selected patients who had a long first remission duration (more than 3 years) and achieved a second molecular remission, other non-transplant options like prolonged arsenic trioxide or autologous transplant (15, 16) can be a valid transplant alternative. The latter options should be compared to allogeneic transplant but the few relapse rate in APL would make prospective randomized trials impractical. It is worth emphasizing the efficacy and feasibility of allogeneic transplants in patients with more resistant or advanced disease.
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